Published on British Columbia Drug and Poison Information Centre (BC DPIC) ( http://www.dpic.org)
Home > Drug Product Listings > Doxepin > Printer-friendly PDF
Doxepin
Trade Name: Silenor Manufacturer/Distributor: Paladin Labs www.paladin-labs.com 1-888-376-7830 Classification: Hypnotic ATC Class: N06AA - doxepin Status: active Notice of Compliance (yyyy/mm/dd): 2012/21/13 Date Marketed in Canada (yyyy/mm/dd): 2012/01/08 Presentation: Tablet: 3 mg. DIN: 02398257 Tablet: 6 mg. DIN: 02398265 Comments: Silenor is indicated for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening, and/or early morning awakenings. Keywords: doxepin sleep disorders hypnotics & sedatives Access: public Back to: Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the Health Canada Drug Product Database Status:
Search Terms: Apply A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4) Date Marketed in Common Generic Name Classification Canada Trade Name(s) (yyyy/mm/dd) Estropipate Ogen Apo-digoxin; Digoxin pms-Digoxin; Lanoxin Panoxyl Clear Salicylic acid + Triclosan Acne Cleansing Gel Risedronate + Calcium Actonel APC carbonate Sibutramine Meridia 2010/10/08 Rosiglitazone + Avandaryl 2011/03/31 glimepiride Phosphate Phosphate Effervescent 2017/01/01 Sandoz Metronidazole with Flagystatin nystatin vaginal cream vaginal cream Orajel teething Benzocaine 2018/05/23 products Palonosetron Aloxi 5TH3 antagonist 2012/03/14 Mifepristone + Mifegymiso Abortifacient 2016/10/21 misoprostol Cilazapril Inhibace ACE inhibitor Adapalene + benzoyl Tactuo Acne therapy 2011/04 peroxide Isotretinoin Epuris Acne therapy 2013-03-14 Acamprosate Campral Alcohol abstinence aid 2007/03 Eplerenone Inspra Aldosterone antagonist 2009/02/26 ALK Tyrosine Kinase Crizotinib Xalkori Inhibitor White birch extract Itulatek Allergy immunotherapy 2020/09/28 (Betula verrucosa) Date Marketed in Common Generic Name Classification Canada Trade Name(s) (yyyy/mm/dd) Alpha adrenergic Midodrine Amantine agonist Alpha adrenergic Guanfacine HCl Intuniv XR receptor agonist for 2013/08/06 ADHD Alpha-1 adrenergic Silodosin Rapaflo 2012/03/05 blocker Alpha-1 blocker + 5- Dutasteride + tamsulosin Jalyn Alpha reductase 2012/02/03 inhibitor Alpha-1 blocker + 5- Tamsulosin + Jalyn Alpha reductase 2012/02/03 dutasteride inhibitor Alpha-2 adrenergic Dexmedetomidine Precedex 2010/02/24 agonist alpha-2 adrenergic Brimonidine Onreltea receptor antagonist for 2014/04/23 rosacea Tramadol Tridural Analgesic Pregabalin Lyrica Analgesic Testosterone Natesto Androgen 2016/05/06 Androgen biosynthesis Abiraterone Zytiga 2011/08/08 inhibitor Propofol Propofol Anesthetic, sedative 2010/06/01 Injection Angiotensin II Telmisartan + antagonists and Twynsta 2011/08/03 amlodipine calcium channel blockers Naltrexone + bupropion Contrave Anorexigenic agents 2018/02/13 Ivermectin Stromectol Anthelmintic 2018/11/07 Dapsone Aczone Anti-acne therapy 2011/10/21 Olopatadine Pataday Anti-allergy agent 2011/04/14 Apalutamide Erleada Anti-androgen 2018/07/27 1 2 3 4 5 6 7 8 9 ? next ? last » © 2017 BC Drug and Poison Information Centre
All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases. Terms and Conditions
Source URL (retrieved on 2021-09-26 17:47): http://www.dpic.org/druglisting/doxepin